Thank you, Katerina, and welcome also from my side to this session.
We will start from the top line and look at invoicing and net sales. We had good growth this quarter. It has continued during the year. In the distribution segment, our existing customers are growing. We have also seen that the new customers we have onboarded have been growing very well. We have in the distribution segment also started with vaccine deliveries slightly earlier than last year. So in September, we have been handling those, which has also generated more invoicing. We are also involved in the wholesale business. We have, as Katharina mentioned, the parallel import, which has generated net sales in that part. Overall, if you look at the year-to-date numbers.
So we are experiencing good growth, mainly driven by the larger distribution business. Sales margin, of course. As I said before, it is crucial for a key performance indicator that we follow closely in the company. We have been growing each quarter, and it's mainly been driven by the distribution business. Now, we also had a good quarter in the wholesale business, generating sales margin. We have, year to date, increased the sales margin by 6.3 million. This is mainly driven by the growth in the business. Driving for more volumes and a higher sales margin. Looking at the EBITDA, we have had a good quarter. As said, wholesale was flat compared to last year. We have had a decline in the EBITDA in wholesale the first two quarters, but now it was flat. And we also have a tight cost control in place. So we try to increase profitability by monitoring the costs very closely. Also, if we look at the adjusting items now, we have much more than last year. It's the ERP project mainly driving those.
We also had the DOE Sweden impacting the adjusting items. And then we have some smaller topics there. We have a feasibility study on the manga distribution center also included in there. But that brings the reported EBITDA down to a lower level of 14.5 million.
If we look at the distribution segment, the good growth is continuing. It's with the new and current customers that we have, and as said, also in the quarter there were some more vaccine deliveries, positively affecting the quarter with a 10% growth year on year. In the first quarters, the EBITDA is growing. It's related to the volume growth and follows the same pace as the beginning of the year. The wholesale segment had good growth, partly dependent on the parallel import related to weight loss medicines in Sweden. A 16% increase year-to-date in adjusted EBITDA.
As stated in the quarter, it was flat.
If we look at the year to date, we are still lower than last year. However, it was a good development during this quarter. If we look at the net profit, we have had, as said, more adjusting items affecting the reported EBITDA. And then we have some other small improvements, but we are landing on a -9.3 million negative net profit, which is lower than last year. Free cash flow, even though we have a lower EBITDA, we have better cash flow mainly related to the working capital items where we have volatility in the working capital. So it might go a bit up and down depending on the reporting day.
But in general, the trend is, of course, towards negative working capital. So the more we invoice and sell, the better the cash flow will be. If we look at the net debt, we see a slight change from the last quarter. But compared to a year ago, we are on a lower level than that. So the net interest-bearing debt has been improving. If we look at the equity ratio, it has now been at a 13% level. We know that this is, of course, as earlier said, affected by the ERP project and impairments that we have had during this year and also last year. We know that the ERP project is burdening the equity ratio, but we know that there will be an end to that also. While we are taking all the costs now in the profit and loss, we know that we will have almost no depreciations from this implementation. After that, the gearing, of course, is on a good level. Due to good cash flow in general. Kronans is doing a bit better this quarter, having a small positive impact on our numbers. Also, uh, good. With Krona, their market share remained stable this quarter.
Not gaining, not losing any market share. They are now finalizing and completing the ERP project and integration project during the last quarter. So, then that will be ready and rolled out.
We are keeping the outlook unchanged.
We are expecting the EBITDA to increase from the previous year. And there is no change on that. Then if we look at the equity ratio and gearing, the equity ratio has now been at a 13% level. That was my part.